Home/Pipeline/CYPS317

CYPS317

Psoriasis

DiscoveryActive

Key Facts

Indication

Psoriasis

Phase

Discovery

Status

Active

Company

FibroBiologics

About FibroBiologics

FibroBiologics is developing a novel class of biologic treatments based on fibroblasts, one of the most abundant cells in the human body. The company claims its fibroblast platform offers superior potency, easier sourcing, and lower manufacturing costs compared to stem cell therapies. With over 270 patents and an IND-cleared program for degenerative disc disease, FibroBiologics is positioning itself as a leader in next-generation regenerative medicine.

View full company profile

Therapeutic Areas

Degenerative Disc Disease Multiple Sclerosis Wound Healing Psoriasis Oncology Diabetes Anti-Aging / Immunosenescence

Other Psoriasis Drugs

Drug	Company	Phase	Status
Taltz (ixekizumab)	Eli Lilly	Approved	Commercial
Ilumya (tildrakizumab)	Sun Pharmaceutical	Approved	Commercial
SCD-044	Sun Pharmaceutical	Phase 2	Active
Itolizumab	Biocon	Approved	Commercial
SCD-105	SPARC	Phase 2	Completed
IMP731	Immutep	Phase 1/Ib	Completed